Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

Abstract:

INTRODUCTION:Non-steroidal anti-inflammatory drugs are associated with a dose and duration-dependent coronary risk. There is little information concerning analgesic-dose ibuprofen, among the most widely used drugs worldwide. OBJECTIVE:Our objective was to measure the risks of acute coronary syndrome (ACS) after dispensing of ibuprofen, versus paracetamol. METHODS:Propensity score 1:2-matched cohorts of ibuprofen or paracetamol treatment episodes (TEs) in Echantillon Généraliste de Bénéficiaires (EGB), the 1/97 sample of Système National des Données de Santé (SNDS), the French nationwide claims database, from 2009 to 2014, were compared. Outcomes were hospital admissions for ACS during the 3 months after the dispensing of ibuprofen or paracetamol. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated overall and stratified on low-dose aspirin dispensing. RESULTS:A total of 315,269 ibuprofen TEs in 168,400 persons were matched to 630,457 paracetamol TEs in 395,952 patients. Event rates were 50-100 times higher in low-dose aspirin users (27 vs 0.28 per 1000 patient years). Overall there was no difference in risk of ACS at 3 months (HR 0.94, 95% CI 0.74-1.20) despite a transient increase in the first 2 weeks in ibuprofen users (HR 1.70, 95% CI 1.11-2.59). In the stratified analysis, this short-term risk was only found in aspirin users (5% of population, HR 1.84, 95% CI 1.24-3.24), but not in non-aspirin users (HR 1.09, 95% CI 0.40-2.94). CONCLUSIONS:There was no evidence for an increased risk of ACS in patients dispensed ibuprofen compared to paracetamol.

journal_name

Drug Saf

journal_title

Drug safety

authors

Duong M,Abouelfath A,Lassalle R,Droz C,Blin P,Moore N

doi

10.1007/s40264-018-0686-7

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

1049-1058

issue

11

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-018-0686-7

journal_volume

41

pub_type

杂志文章
  • Comment on: "All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population".

    abstract:: ...

    journal_title:Drug safety

    pub_type: 评论,信件

    doi:10.1007/s40264-018-0670-2

    authors: Kawada T

    更新日期:2018-06-01 00:00:00

  • Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

    abstract::Probiotics have seen widespread use for a variety of gastrointestinal problems, especially in two common disorders: irritable bowel syndrome and inflammatory bowel disease. Since a wide variety of probiotic preparations has been used, and despite a large number of studies performed, a great deal of heterogeneity exist...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0349-x

    authors: Bennett WE Jr

    更新日期:2016-04-01 00:00:00

  • Patient Reporting in the EU: Analysis of EudraVigilance Data.

    abstract:INTRODUCTION:New pharmacovigilance legislation was adopted in the EU in 2010 and became operational in July 2012. The legislation placed an obligation on all national competent authorities (NCAs) and marketing authorisation holders (MAHs) to record and report cases of suspected adverse drug reactions (ADRs) received fr...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0534-1

    authors: Banovac M,Candore G,Slattery J,Houÿez F,Haerry D,Genov G,Arlett P

    更新日期:2017-07-01 00:00:00

  • A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch.

    abstract::To estimate the frequency of adverse effects associated with the use of the transdermal nicotine patch, we abstracted and analysed data from 47 reports of 35 clinical trials. The meta-analysis presented here represents a synthesis of data from 41 groups of nicotine patch recipients totalling 5501 patients, and 33 grou...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析

    doi:10.2165/00002018-199818040-00005

    authors: Greenland S,Satterfield MH,Lanes SF

    更新日期:1998-04-01 00:00:00

  • Poisoning by thallium. A study of five cases.

    abstract::Thallium poisoning seldom occurs in Spain. This article reports 5 cases of thallium poisoning, of which 4 of the patients belonged to the same family. The cases occurred in or near Granada between 1985 and 1987. The symptoms were initially gastrointestinal (vomiting, abdominal pain, gastrointestinal haemorrhage, etc.)...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199005050-00006

    authors: Villanueva E,Hernandez-Cueto C,Lachica E,Rodrigo MD,Ramos V

    更新日期:1990-09-01 00:00:00

  • Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

    abstract:BACKGROUND:An association between oral contraceptive (OC) use and venous thromboembolism (VTE) has long been recognized. However, no summary estimates of the increase in VTE risk associated with OC use have been available since 1995, and no meta-analyses have evaluated the VTE risk of new preparations containing drospi...

    journal_title:Drug safety

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/11598050-000000000-00000

    authors: Manzoli L,De Vito C,Marzuillo C,Boccia A,Villari P

    更新日期:2012-03-01 00:00:00

  • Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

    abstract:BACKGROUND:Psoriasis is a chronic autoimmune disease characterized by infiltration of the dermis and epidermis by activated T cells and the hyperproliferation and abnormal differentiation of keratinocytes. It is a life-long disease with alternating periods of remission and recurrence. Efalizumab is a humanized, recombi...

    journal_title:Drug safety

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00002018-200831080-00008

    authors: Hamilton T,Menter A,Caro I,Compton P,Sobell J,Papp KA

    更新日期:2008-01-01 00:00:00

  • Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

    abstract:BACKGROUND:Several efforts are under way to develop and test methods for prospective drug safety monitoring using large, electronic claims databases. Prospective monitoring systems must incorporate signalling algorithms and techniques to mitigate confounding in order to minimize false positive and false negative signal...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11594770-000000000-00000

    authors: Wahl PM,Gagne JJ,Wasser TE,Eisenberg DF,Rodgers JK,Daniel GW,Wilson M,Schneeweiss S,Rassen JA,Patrick AR,Avorn J,Bohn RL

    更新日期:2012-05-01 00:00:00

  • Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

    abstract::Pharmacovigilance science has traditionally been a discipline focussed on the postmarketing or post-authorisation period, with due attention directed towards pre-clinical safety data, clinical trials and adverse events. As the biological sciences have evolved, pharmacovigilance has slowly shifted toward earlier, proac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629080-00003

    authors: Hartford CG,Petchel KS,Mickail H,Perez-Gutthann S,McHale M,Grana JM,Marquez P

    更新日期:2006-01-01 00:00:00

  • A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database.

    abstract:BACKGROUND:The detection of new drug safety signals is of growing importance with ever more new drugs becoming available and exposure to medicines increasing. The task of evaluating information relating to safety lies with national agencies and, for international data, with the World Health Organization Programme for I...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023060-00004

    authors: Lindquist M,Ståhl M,Bate A,Edwards IR,Meyboom RH

    更新日期:2000-12-01 00:00:00

  • Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers.

    abstract::Several anticancer drugs have been associated with cardiac toxicity, especially the anthracyclines and trastuzumab. The pathogenesis of anthracycline-associated toxicity has been well described, whereas the mechanism of trastuzumab-associated toxicity is unknown. Although routine cardiac imaging studies (e.g. echocard...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225050-00001

    authors: Sparano JA,Brown DL,Wolff AC

    更新日期:2002-01-01 00:00:00

  • Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach.

    abstract::The New Zealand Intensive Medicines Monitoring Programme (IMMP) undertakes prospective observational cohort studies on selected new drugs in the early postmarketing period using prescription-event monitoring (PEM) methodology with the purpose of identifying signals of previously unrecognised ADRs and establishing risk...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200225060-00007

    authors: Coulter DM

    更新日期:2002-01-01 00:00:00

  • Adverse reactions to drugs as a cause of admissions to a general teaching hospital in Hong Kong.

    abstract::To determine the pattern of and the risk factors for adverse drug reactions (ADRs) in Hong Kong, a prospective study of acute admissions to 2 general medical wards at the Prince of Wales Hospital was undertaken. Of the 1701 admissions included in this study, 74 (4.4%) were attributed to ADRs. Sulphonylureas, nonsteroi...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199207030-00008

    authors: Chan TY,Chan JC,Tomlinson B,Critchley JA

    更新日期:1992-05-01 00:00:00

  • Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.

    abstract::Benefit-risk assessment should be ongoing during the life cycle of a pharmaceutical agent. New products are subjected to rigorous registration laws and rules, which attempt to assure the availability and validity of evidence. For older products, bias in benefit-risk assessment is more likely, as a number of safeguards...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932040-00003

    authors: De Backer TL,Vander Stichele RH,Van Bortel LM

    更新日期:2009-01-01 00:00:00

  • beta-blockers. Drug interactions of clinical significance.

    abstract::The clinician prescribing beta-blockers for his or her patients is faced with an often difficult situation. There are many beta-blockers, each with its own pharmacological profile. Patients are often taking multiple medications, thus increasing the risk of both anticipated and unexpected drug interactions. Reports of ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199513060-00005

    authors: Blaufarb I,Pfeifer TM,Frishman WH

    更新日期:1995-12-01 00:00:00

  • Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.

    abstract:INTRODUCTION:Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators and biosimilars) are limited. In light of current debate about interchangeability, prescribers, some patient groups and decision makers are calling for additional post-marketing evidence...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00845-y

    authors: Belleudi V,Trotta F,Addis A,Ingrasciotta Y,Ientile V,Tari M,Gini R,Pastorello M,Scondotto S,Cananzi P,Traversa G,Davoli M,Trifirò G,Italian Biosimilar Network (ItaBioNet).

    更新日期:2019-12-01 00:00:00

  • Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.

    abstract:INTRODUCTION:Adverse drug events (ADEs) may represent an important item of expenditure for healthcare systems and their prevention could be associated with a relevant cost saving. OBJECTIVE:The objective of this study was to simulate the annual economic burden for ADEs in Tuscany (Italy) and the potential cost savings...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-018-0737-0

    authors: Convertino I,Salvadori S,Pecori A,Galiulo MT,Ferraro S,Parrilli M,Corona T,Turchetti G,Blandizzi C,Tuccori M

    更新日期:2019-03-01 00:00:00

  • Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

    abstract::Data from basic science and clinical studies suggest that hydroxyurea (hydroxycarbamide)-based regimens are effective treatment options for patients with HIV at various stages of disease. In vitro studies of HIV-infected lymphocytes have shown that hydroxyurea: (i) inhibits viral DNA synthesis; (ii) synergistically in...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326090-00002

    authors: Lisziewicz J,Foli A,Wainberg M,Lori F

    更新日期:2003-01-01 00:00:00

  • Carbamazepine overdose. Features of 33 cases.

    abstract::Review of the medical records of 2 major adult teaching hospitals for a 4-year period revealed 33 instances of carbamazepine overdose. These patients had a mean age of 30 years and 58% were known epileptics. They ingested a mean of 12g carbamazepine (range 1.6 to 45g), with 51% of cases involving other drugs, particul...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199308010-00010

    authors: Seymour JF

    更新日期:1993-01-01 00:00:00

  • Post-approval safety issues with innovative drugs: a European cohort study.

    abstract:BACKGROUND:At time of approval, knowledge of the full benefit risk of any drug is limited, in particular with regards to safety. Post-approval surveillance of potential drug safety concerns is recognized as an important task of regulatory agencies. For innovative, often first-in-class drugs, safety knowledge at time of...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0094-y

    authors: Mol PG,Arnardottir AH,Motola D,Vrijlandt PJ,Duijnhoven RG,Haaijer-Ruskamp FM,de Graeff PA,Denig P,Straus SM

    更新日期:2013-11-01 00:00:00

  • Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study.

    abstract:INTRODUCTION:Pharmacovigilance, the monitoring of drug safety after marketing approval, highly depends on the adequate reporting of adverse drug reactions (ADRs). To improve pharmacovigilance awareness and future ADR reporting among medical students, we developed and evaluated a student-run pharmacovigilance programme....

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0502-1

    authors: Schutte T,Tichelaar J,Reumerman MO,van Eekeren R,Rolfes L,van Puijenbroek EP,Richir MC,van Agtmael MA

    更新日期:2017-05-01 00:00:00

  • The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

    abstract::All national guidelines for the management of hypertension recommend angiotensin receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The eight available ARBs have variable clinical efficacy when used for control of hypertension. Additive blood pressure-lowering effects have been demonstrated whe...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-014-0239-7

    authors: Abraham HM,White CM,White WB

    更新日期:2015-01-01 00:00:00

  • Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries.

    abstract:BACKGROUND:Acute liver failure is idiopathic and drug-related in, respectively, around 50 and 15 % of children. Population-based, epidemiologic data about the pattern of disease manifestation and incidence of less severe acute liver injury, either idiopathic or potentially drug-attributed are limited in children and ad...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0045-7

    authors: Ferrajolo C,Verhamme KM,Trifirò G,'t Jong GW,Giaquinto C,Picelli G,Oteri A,de Bie S,Valkhoff VE,Schuemie MJ,Mazzaglia G,Cricelli C,Rossi F,Capuano A,Sturkenboom MC

    更新日期:2013-10-01 00:00:00

  • Association between leukotriene-modifying agents and suicide: what is the evidence?

    abstract::The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LT...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11587260-000000000-00000

    authors: Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RD

    更新日期:2011-07-01 00:00:00

  • Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

    abstract::Although the aetiology of inflammatory bowel disease remains elusive, many agents are available for the control of symptoms and inflammation. Knowledge of drug pharmacology, indications and side effects is essential to ensure the best possible clinical care while minimising toxicity and inappropriate use. Sulfasalazin...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199106030-00005

    authors: Hanauer SB,Stathopoulos G

    更新日期:1991-05-01 00:00:00

  • Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis.

    abstract::Intranasal corticosteroids and intranasal antihistamines are efficacious topical therapies in the treatment of allergic rhinitis. This review addresses their relative roles in the management of this disease, focusing on their safety and tolerability profiles. The intranasal route of administration delivers drug direct...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326120-00003

    authors: Salib RJ,Howarth PH

    更新日期:2003-01-01 00:00:00

  • Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

    abstract:BACKGROUND:Case reports have related the use of HMG-CoA reductase inhibitors ('statins') to Parkinson's disease (PD). Paradoxically, however, statins may have potentially beneficial effects on neurodegenerative diseases due to their anti-inflammatory properties. OBJECTIVE:To explore the risk of the development of PD i...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200831050-00004

    authors: Becker C,Jick SS,Meier CR

    更新日期:2008-01-01 00:00:00

  • Risk perception and communication in sub-Saharan Africa.

    abstract::In this narrative review, a brief summary of theoretical approaches to risk perception is followed by an analysis of some of the special factors influencing risk perception and risk communication in sub-Saharan Africa. Examples of recent and emergent local medicines and vaccine controversies in several countries are g...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/BF03261990

    authors: Dodoo A,Hugman B

    更新日期:2012-11-01 00:00:00

  • The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

    abstract::Antibiotic-associated pseudomembranous colitis is an uncommon but potentially serious adverse reaction, resulting in acute diarrhoea and characterised by colonic pseudomembranes. A direct relationship between the disease, recent antibiotic therapy and proliferation of Clostridium difficile in the colonic lumen was est...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199106050-00004

    authors: Andréjak M,Schmit JL,Tondriaux A

    更新日期:1991-09-01 00:00:00

  • A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.

    abstract:INTRODUCTION:An often key component to coordinating surveillance activities across distributed networks is the design and implementation of a common data model (CDM). The purpose of this study was to evaluate two drug safety surveillance CDMs from an ecosystem perspective to better understand how differences in CDMs an...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-015-0297-5

    authors: Xu Y,Zhou X,Suehs BT,Hartzema AG,Kahn MG,Moride Y,Sauer BC,Liu Q,Moll K,Pasquale MK,Nair VP,Bate A

    更新日期:2015-08-01 00:00:00